GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

• Conditions: Elderly Unfit Patients; CD20 Positive Diffuse Large B-cell Lymphoma
• Interventions: Drug: Ga101

• Registration Number: NCT02495454
• Lead Sponsor: Fondazione Italiana Linfomi - ETS

Brief Summary

GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell non-Hodgkin's lymphoma.

Detailed Description

Considering that the treatment of elderly unfit patients with DLBCL cannot be based on a full course of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone), and that using a less intense R-miniCHOP (an attenuated version of the standard R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) combination an acceptable cure rate can be achieved this study is designed to try to improve the cure rate in unfit patients with DLBCL (Diffuse Large B Cell Lymphoma) by adopting the R-miniCHOP scheme substituting Rituximab with the more active GA101 monoclonal antibody. The study hypothesis is that a higher activity of the treatment can be achieved without modifying the cytotoxic part of the treatment but using a more active immunotherapy. Differently from the previous experience with R-miniCHOP eligible patient are not only identified using anagraphic criteria but adopting CGA (Comprehensive Geriatric Assessment) as part of initial assessment and considering as eligible unfit patients.

Study Timeline

• Study First Submitted: 2015-06-08
• Study First Submitted QC: 2015-07-08
• Study First Posted: 2015-07-13
• Study Start: 2015-08-25
• Primary Completion: 2017-03-22
• Study Completion: 2017-03-22
• Status Verified: 2020-08
• Results First Submitted: 2020-08-20
• Results First Submitted QC: 2020-11-04
• Last Update Submitted: 2020-11-04
• Results First Posted: 2020-11-05
• Last Update Posted: 2020-11-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

1. Histologically proven CD20 positive Diffuse Large B-cell Lymphoma and Follicular grade III B lymphoma, according to WHO (World Health Organization) classification (local pathologist)

2. Age ≥ 65 years

3. No previous treatment

4. CGA assessment (Comprehensive Geriatric Assessment) performed before starting treatment

5. Unfit patients defined as follows:

   Age > 80 years with Fit profile, i.e. ADL (Activity of Daily Living) =6 residual functions IADL (Instrumental Activity of Daily Living) =8 residual functions CIRS (Cumulative Illness Rating Scale): no comorbidity of grade 3-4 and <5 of grade 2 or Age < 80 with Unfit profile, i.e ADL(Activity of Daily Living) > 5 residual functions IADL (Instrumental Activity of Daily Living) > 6 residual functions CIRS (Cumulative Illness Rating Scale): no comorbidity of grade 3-4 and 5-8 co-morbidities of grade 2

6. Ann Arbor Stage I with bulky, II-IV

7. At least one bi-dimensionally measurable lesion defined as > 1.5 cm in its largest dimension on CT scan

8. ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2

9. Adequate hematologic function (unless caused by bone marrow infiltrate), defined as follows:

   Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L

10. LVEF (Left Ventricular Ejection Fraction) >50%

11. Ability and willingness to comply with the study protocol procedure

12. Life expectancy > 6 months

13. Accessibility of patient for treatment and follow up

14. Written informed consent

Exclusion Criteria

1. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
2. Contraindication to any of the individual components of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone), including prior receipt of anthracyclines
3. History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
4. Stage I without bulky
5. Patients with transformed lymphoma
6. Prior therapy for DLBCL (Diffuse Large B Cell Lymphoma), with the exception of nodal biopsy or local irradiation
7. Previous exposure to cytotoxic agents
8. Suspect or clinical evidence of CNS (Central Nervous System) involvement by lymphoma
9. HBsAg (Hepatitis B surface antigen), HCV (Hepatitis C Virus) or HIV (Human Immunodeficiency Virus) positivity; isolated HBcAb (Hepatitis B surface antibody) positivity is accepted only with concomitant treatment with Lamivudine
10. AST /ALT (Aspartate Aminotransferase/Alanine Aminotransferase)> twice upper the normal range; bilirubin > twice upper the normal range; serum creatinine > 2.5 mg /dl (unless these abnormalities were related to the lymphoma)
11. Evidence of any severe active acute or chronic infection
12. Concurrent co-morbid medical condition which might exclude administration of full dose chemotherapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ga101-miniCHOP	Ga101	6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101). GA101-miniCHOP regimen: * Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os * Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os * Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days.

Primary Outcome Measures

Name	Time	Method
Complete Response Rate (CRR). Based a Central Independent Review Committee Considering Use the Conventional CT Scan Images.	Up to 36 months.	Complete Response Rate after 10 infusions of GA101 and 6 cycles of miniCHOP. Complete Remission (CR): Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, normalization of biochemistry abnormalities. If the bone marrow was involved by lymphoma before treatment, the infiltrate must be cleared on repeat bone marrow aspirate and biopsy of the same site. Partial disease (PR): \>= 50% decrease in node diameter of the six largest dominant nodes or nodal masses and no new sites of disease; Stable disease (SD): is defined as less than a PR but is not progressive disease. Progession disease (PD): \>50% increase diameter of node from nadir of any previously identified abnormal node nonresponders, and/or appearance of any new lesion.

Secondary Outcome Measures

Name	Time	Method
Instrumental Activities of Daily Living (IADL)	Up to 36 months	Change in Instrumental Activities of Daily Living score. The score ranging from 0 (bad performance) to 8 (good performance).
Cumulative Illness Rating Scale (CIRS)	Up to 36 months	Change in Cumulative Illness Rating Scale. The grading of comorbidity ranging from 0 (absent) to 4 (severe).
Questionnaire for Quality of Life (EORTC QLQ C30)	Up to 36 months	Change in quality of life (QoL)
OS (Overall Survival)	Up to 36 months	OS (Overall Survival): defined as the time from the date of treatment start into the study until the date of death irrespective of cause. Patients who have not died at the time of end of the whole study, and patients who are lost to follow up, will be censored at the date of the last contact.
PFS (Progression Free Survival)	Up to 36 months	PFS (Progression Free Survival): defined as the time from entry into the study until lymphoma relapse/ progression or death as a result of any cause. Responding patients, patients who are lost to follow up, who withdrawal the consent or drop-out due to adverse event will be censored at their last assessment date. Patients died due to tumor will be considered in progression. Patients died for any other cause will be censored to the death date.
Activities of Daily Living (ADL)	Up to 36 months	Change in Activities of daily living score. The score ranging from 0 (bad performance) to 6 (good performance)
Adverse Events (AEs)	Up to 36 months	Rate of Adverse Events. Although was not defined a formal threshold, in this section we reported the summary of frequencies of maximum CTCAE observed in patients. Each patient was counted only once within the AE terms during the therapy. If, during the therapy the patient experiences more than one AE, only the AE with the greatest intensity was included in the summary.
Partial Response Rate (PRR)	Up to 36 months	Partial Response Rate (PRR): patients in Partial Response after induction therapy.; Frequency of PRR already reported in the table of principal end-point.
ORR (Overall Response Rate)	Up to 36 months	ORR (Overall Response Rate): sum of patiens with Complete or Partial response after the induction therapy.

Trial Locations

Locations (16)

Asmn-Irccs; 🇮🇹 Reggio Emilia, RE, Italy

Ematologia 1U - AO Città della Salute e della Scienza; 🇮🇹 Torino, TO, Italy

A.O. S. Maria di Terni; 🇮🇹 Terni, TR, Italy

A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona; 🇮🇹 Ancona, Italy

Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI; 🇮🇹 Varese, Italy

Irccs Istituto Oncologico Veneto (Iov); 🇮🇹 Padova, Italy

Oncoematologia e TMO Dopartimento Oncologia La Maddalena; 🇮🇹 Palermo, Italy

Ausl Di Rimini; 🇮🇹 Rimini, Italy

AUSL di Ravenna; 🇮🇹 Ravenna, RA, Italy

A.O. Spedali Civili; 🇮🇹 Brescia, BS, Italy

SCDU Ematologia - Università del Piemonte Orientale; 🇮🇹 Novara, Italy

A.O. SS. Antonio e Biagio e C. Arrigo; 🇮🇹 Alessandria, Italy

A.O. Ospedale Degli Infermi; 🇮🇹 Biella, Italy

Area Vasta Romagna e IRST; 🇮🇹 Meldola (FC), Italy

IRCCS, Istituto Nazionale dei Tumori; 🇮🇹 Milano, Italy

A.O. Universitaria Policlinico Di Modena; 🇮🇹 Modena, Italy